Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients

Psychopharmacology

Volumn 190, Issue 4, 2007, Pages 479-484

  Gunes, Arzu ^a   Scordo, Maria Gabriella ^a   Jaanson, Peeter ^b   Dahl, Marja Liisa ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Extrapyramidal side effects; Perphenazine; Receptor gene polymorphisms; Schizophrenia

Indexed keywords

BENZODIAZEPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PERPHENAZINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TRIHEXYPHENIDYL;

ADOLESCENT; ADULT; AGED; AKATHISIA; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COVARIANCE; DNA POLYMORPHISM; EVALUATION; EXTRAPYRAMIDAL SYNDROME; FEMALE; GENDER; GENE FREQUENCY; GENOTYPE; HOSPITAL PATIENT; HUMAN; MALE; MONOTHERAPY; NEUROLOGIC DISEASE; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RATING SCALE; RISK; SCHIZOPHRENIA; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PERPHENAZINE; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN; RISK FACTORS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846820225     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0622-x     Document Type: Article

References (41)

1. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT (2004) Metaanalysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67:53-62
2. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA (2005) Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55:242-251
3. Arinami T, Itokawa M, Enguchi H, Tagaya H, Yano S, Shimizu H, Hamaguchi H, Toru M (1994) Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343:703-704
4. Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582
5. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615-1616
6. Casey DE (1991) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109-120
7. Cravchik A, Sibley DR, Gejman PV (1996) Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 271:26013-26017
8. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC et al (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 29:858-860
9. Dahl ML (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453-470
10. Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001) Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229-232
11. Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002) Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71:727-734
12. Eberle-Wang K, Lucki I, Chesselet MF (1996) A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72:117-128
13. Grandy DK, Zhang Y, Civelli O (1993) PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 2:2197
14. Hansen LB, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berl) 87:16-19
15. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O (2006) Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 26:192-197
16. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290-296
17. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D (1995) Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 27:274-279
18. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27:105-119
19. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F (2005) Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8:411-425
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
21. Malhotra AK, Murphy GM, Jr., Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796
22. Mandal TK, Ace LN (1993) High-performance liquid chromatographic determination of perphenazine in plasma. J Clin Pharm Ther 18:205-208
23. Melkersson K, Dahl ML (2004) Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64:701-723
24. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
25. Milatovich A, Hsieh CL, Bonaminio G, Tecott L, Julius D, Francke U (1992) Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4). Hum Mol Genet 1:681-684
26. Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P (1999) Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 19:203-208
27. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D (2004) Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 9:55-64
28. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE, Goldman D (1997) A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 68:2186-2193
29. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ (2004) The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 56:406-410
30. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3:256-260
31. Polesskaya OO, Sokolov BP (2002) Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67:812-822
32. Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3:201-218
33. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, Dorevitch A, Yakir A, Lerner A, Shelevoy A, Lerer B (1999) Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 4:247-253
34. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152:408-413
35. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7:169-172
36. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, Murphy KC, Jones L, Buckland PR, McGuffin P, Lesch KP, Owen MJ (1998) A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 3:42-49
37. Stewart BR, Jenner P, Marsden CD (1989) Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs. Eur J Pharmacol 162:101-107
38. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA (1997) D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7:479-484
39. Warren JT Jr., Peacock ML, Rodriguez LC, Fink JK (1993) An MspI polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 2:338
40. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K (2000) Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 43:373-376
41. Zhang ZJ, Zhang XB, Sha WW, Zhang XB, Reynolds GP (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7:670-671